No Data
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Shandong Buchang Pharmaceuticals Terminates Agreements With Nantong Lianya Pharmaceutical
Shandong Buchang Pharmaceuticals (603858.SH): Plans to give up the preferential acquisition of equity in its controlling subsidiaries.
Gelonghui, December 26 - Shandong Buchang Pharmaceuticals (603858.SH) announced that its controlling subsidiary Shanghai Hupu's shareholder Wang Baocai intends to transfer his unpaid 0.05% equity in Shanghai Hupu to Zhao Xiaogang at a transaction price of 0 yuan, and intends to transfer his unpaid 0.025% equity in Shanghai Hupu to Cheng Kai at a transaction price of 0 yuan. The company agrees to waive its preemptive rights, and after the transaction is completed, the company will maintain its 71.30% equity stake in Shanghai Hupu.
Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?
Shandong Buchang Pharmaceuticals (603858.SH): Application for clinical trials of the varicella attenuated live vaccine has been accepted.
Shandong Buchang Pharmaceuticals (603858.SH) announced that its controlling subsidiary Zhejiang Tianyuan Biopharmaceutical Co., Ltd.'s "...
Buchang Pharmaceuticals Gets Drug Registration for Donepezil Hydrochloride Tablets
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago
